Management of autoimmune neuropathies has remained unchanged for much of the past 30 years, but recent advances are changing the rate of progress. In this Review, the authors summarize the latest developments, including discoveries in disease mechanisms, new diagnostic guidelines, identification of new biomarkers and the status of promising clinical trials.